ABVX Abivax S.A. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1956827 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-90.7%
TTM EPS YoY-72.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-135.6%
ROA-85.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.1%
Debt / equity0.00x
Current ratio8.75x
Interest coverage-2.15x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-44.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 177.76M | 146.53M | 103.18M | 48.30M | 47.78M |
| SG&A expense | 67.67M | 32.95M | 22.39M | 7.49M | 5.58M |
| Operating income | -246.06M | -172.98M | -127.38M | -64.84M | -41.40M |
| Interest expense | 111.74M | 16.99M | 27.88M | 7.02M | 3.56M |
| Pretax income | -330.25M | -176.24M | -147.74M | -60.74M | -42.45M |
| Income tax | 5.85M | 0 | 0 | 0 | 0 |
| Net income | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
| EBITDA | -244.98M | -171.88M | -126.67M | -64.35M | -41.10M |
| EPS (basic) | -4.83 | -2.80 | -3.43 | -3.18 | -2.75 |
| EPS (diluted) | -4.83 | -2.80 | -3.43 | -3.18 | -2.75 |
| Weighted avg. shares (diluted) | 69.53M | 63.05M | 43.07M | 19.09M | 15.46M |
| Balance sheet | |||||
| Cash & equivalents | 516.68M | 144.22M | 251.94M | 26.95M | 60.70M |
| Short-term investments | 0 | 136,000 | 136,000 | 0 | 0 |
| Current assets | 551.24M | 170.67M | 285.97M | 36.18M | 75.48M |
| PP&E, netmay include right-of-use assets (IFRS) | 2.09M | 2.67M | 878,000 | 1.59M | 305,000 |
| Goodwill | 18.42M | 18.42M | 18.42M | 18.42M | 32.01M |
| Intangibles | 6.61M | 6.61M | 6.60M | 6.61M | 93,000 |
| Total assets | 584.34M | 205.23M | 327.06M | 75.54M | 109.23M |
| Current liabilities | 63.02M | 94.00M | 90.69M | 51.46M | 32.27M |
| Total liabilities | 129.14M | 164.64M | 131.05M | 68.36M | 83.30M |
| Shareholders' equity | 455.20M | 40.58M | 196.01M | 7.19M | 25.93M |
| Shares outstanding | — | 63.35M | 62.92M | 22.30M | 16.76M |
| Cash flow statement | |||||
| Operating cash flow | -161.13M | -154.07M | -97.13M | -53.94M | -45.05M |
| Capital expenditure | 142,000 | 640,000 | 265,000 | 288,000 | 47,000 |
| Free cash flow | -161.27M | -154.71M | -97.39M | -54.22M | -45.09M |
| Investing cash flow | -8.19M | 15.76M | -8.10M | -12.03M | -6.23M |
| Financing cash flow | 547.31M | 28.21M | 335.29M | 32.21M | 82.68M |
| Depreciation & amortization | 1.07M | 1.10M | 707,000 | 485,000 | 302,000 |
| Stock-based compensation | 35.40M | 20.22M | 8.18M | -1.16M | 828,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.